S

SAB BIO Tech Stack

Clinical-stage immunotherapy platform targeting type 1 diabetes onset and progression

Biotechnology Research Miami, FL 51–200 employees Public Company

SAB Bio is a clinical-stage biopharmaceutical company developing a fully-human anti-thymocyte immunoglobulin (hIgG) for type 1 diabetes. The project mix—spanning bovine cloning protocols, cell line establishment, bench-scale protein purification, and biomarker discovery—reflects a company scaling from lab validation toward manufacturing readiness. Pain points around production yield, purification efficiency, and regulatory audit compliance indicate the organization is transitioning from research-focused to production-focused operations, mirrored by their 5-strong manufacturing team.

Tech Stack 18 technologies

Core StackSmartsheet Asana DocuSign Active Directory Word Excel PowerPoint Outlook Microsoft Office Microsoft Project LinkSquares Windows Android iOS Microsoft 365 Microsoft Entra ThreatLocker Microsoft Defender

What SAB BIO Is Building

◆Challenges

Improving production output
Increasing purification yield and purity
Complex autoimmune diseases
Biomarker discovery challenges
Maintaining it compliance
Meeting regulatory audits
Ensuring data traceability

▲Active Projects

Bovine cloning protocols
Media formulation for cloning and cell culture units
Cell line establishment and cryopreservation
Bench-scale protein purification
Purification method development
Chromatography software method creation
Novel multi-specific immunotherapy platform
Biomarker discovery
Patient stratification assays
New assay development

Hiring Activity

Accelerating10 roles · 8 in 30d

Department

Manufacturing

5

Research

3

Ops

2

Seniority

Junior

3

Intern

2

Senior

2

Director

1

Manager

1

Mid

1

Notable leadership hires: Director Immunology

Company intelligence

Find more companies like SAB BIO by tech stack, pain points and active projects

Get started free

About SAB BIO

SAB Bio is a clinical-stage biopharmaceutical company headquartered in Miami, Florida, with 51–200 employees. The company is developing a novel immunotherapy platform centered on fully-human anti-thymocyte immunoglobulin (hIgG) aimed at delaying onset or progression of type 1 diabetes. Core operations span cell biology (cloning, cell line establishment, cryopreservation), protein engineering (bench-scale purification, chromatography method development), biomarker discovery, and patient stratification assay development. Tech infrastructure is standard enterprise Microsoft (Office 365, Entra, Defender) and lightweight operational tools (Asana, Smartsheet, LinkSquares), typical for clinical-stage biotech. The company is actively hiring across manufacturing, research, and operations with accelerating velocity.

HeadquartersMiami, FL

Company Size51–200 employees

Hiring MarketsUnited States

Frequently Asked Questions

What is SAB Bio developing?

A fully-human anti-thymocyte immunoglobulin (hIgG) immunotherapy designed to delay onset or progression of type 1 diabetes. The platform is in clinical-stage development.